ArticleCurrent oncology (Toronto, Ont.)2026

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.

Christopher Lemieux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.